News
GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback